Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
89.4M
-
Number of holders
-
168
-
Total 13F shares, excl. options
-
69.7M
-
Shares change
-
-46.6K
-
Total reported value, excl. options
-
$1.72B
-
Value change
-
-$12K
-
Put/Call ratio
-
0.29
-
Number of buys
-
82
-
Number of sells
-
-77
-
Price
-
$24.64
Significant Holders of Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX) as of Q3 2022
201 filings reported holding TVTX - Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q3 2022.
Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX) has 168 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 69.7M shares
of 89.4M outstanding shares and own 77.99% of the company stock.
Largest 10 shareholders include ARMISTICE CAPITAL, LLC (5.84M shares), RA CAPITAL MANAGEMENT, L.P. (4.92M shares), BlackRock Inc. (4.56M shares), Deep Track Capital, LP (4M shares), JANUS HENDERSON GROUP PLC (3.91M shares), STATE STREET CORP (3.41M shares), VANGUARD GROUP INC (3.38M shares), MACQUARIE GROUP LTD (3.31M shares), BAKER BROS. ADVISORS LP (3.3M shares), and GOLDMAN SACHS GROUP INC (2.55M shares).
This table shows the top 168 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.